On March 29, 2023 ProQR will host a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce initial pipeline targets for internal development.
… ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology LEIDEN, the Netherlands, Jan. 08, … fibrosis targets,” said Daniel A. de Boer, CEO of ProQR. “We look forward to working closely with the team at …
… ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets Agreement … FERRAND, France, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company …
… European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10 Access … vision with sepofarsen,” stated Daniel A. de Boer, CEO of ProQR. “Looking ahead, our goal is for sepofarsen to reach …